PMID: 6990666Jan 1, 1980Paper

Baseline pharmacology, electrophysiology and pharmacokinetics of mexiletine

Acta cardiologica. Supplementum
D Middleton

Abstract

Mexiletine is effective in abolishing experimentally induced cardiac arrhythmias and belongs to the Vaughan-Williams Class I group of antiarrhythmic agents. It depresses the maximum rate of depolarisation with little or no modification of resting potentials or the duration of action potentials. When given intravenously mexiletine redistributes rapidly from plasma to tissues after a single intravenous injection. Therapeutic plasma concentrations lie in the region of 1-2 mcg/ml and in order to achieve these concentrations rapidly an initial loading dose is desirable. After oral administration it is rapidly and well adsorbed. An initial oral loading dose is advisable to achieve constant adequate plasma concentrations. The prior administration of opiates may delay oral absorption but this is compensated for by a larger initial loading dose. The half-life may vary under certain circumstances and lies in the region of 10-16 hours. Some 10-15% is excreted unchanged in the urine within 72 hours of oral administration. Mexiletine is largely metabolised in the liver and although there is some renal excretion with pH dependent tubular reabsorption, in clinical practice this has not presented any major problems.

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

British Journal of Clinical Pharmacology
M A KiddieT R Shaw
Archives des maladies du coeur et des vaisseaux
P Touboul
European Journal of Drug Metabolism and Pharmacokinetics
L AllanR F Palmer
© 2021 Meta ULC. All rights reserved